Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Long-Term Investments (2021 - 2023)

Cullinan Therapeutics has reported Long-Term Investments over the past 3 years, most recently at $13.5 million for Q3 2023.

  • Quarterly results put Long-Term Investments at $13.5 million for Q3 2023, down 55.88% from a year ago — trailing twelve months through Sep 2023 was $13.5 million (down 55.88% YoY), and the annual figure for FY2022 was $80.9 million, down 42.39%.
  • Long-Term Investments for Q3 2023 was $13.5 million at Cullinan Therapeutics, down from $18.6 million in the prior quarter.
  • Over the last five years, Long-Term Investments for CGEM hit a ceiling of $140.4 million in Q4 2021 and a floor of $13.5 million in Q3 2023.
  • Median Long-Term Investments over the past 3 years was $80.9 million (2022), compared with a mean of $73.7 million.
  • Peak annual rise in Long-Term Investments hit 197.09% in 2022, while the deepest fall reached 75.31% in 2022.
  • Cullinan Therapeutics' Long-Term Investments stood at $140.4 million in 2021, then plummeted by 42.39% to $80.9 million in 2022, then tumbled by 83.25% to $13.5 million in 2023.
  • The last three reported values for Long-Term Investments were $13.5 million (Q3 2023), $18.6 million (Q2 2023), and $110.4 million (Q1 2023) per Business Quant data.